The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Optimizing frontline treatment for PTCL: introducing novel agents into CHOP-based regimens
Neha Mehta-Shah, MD, MSCI, Washington University, St Louis, MO, discusses the potential of integrating novel agents, such as azacitidine or duvelisib, into traditional CHOP-based regimens to optimize frontline treatment for peripheral T-cell lymphoma (PTCL). She also mentions studies investigating markers of dynamic response to allow adjustments to therapy for those who are not benefitting. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
NMS has served as a consultant for Kyowa Hakko Kirin, Secura Bio, AstraZeneca, Genentech/Roche, Janssen Oncology. NMS has institutional research funding from Bristol Myers Squibb (Inst), Genentech/Roche (Inst), Celgene (Inst), Verastem (Inst), Innate Pharma (Inst), Corvus Pharmaceuticals (Inst), AstraZeneca (Inst), C4 Therapeutics (Inst), Daiichi Sankyo (Inst), Yingli Pharma (Inst), Dizal Pharma (Inst), Secura Bio (Inst), Morphosys (Inst). She is supported by the Leukemia Lymphoma Society as a Scholar in Clinical Research.
